Foundation Medicine's Revenues Grow 39 Percent in Q4, Net Loss Widens | GenomeWeb

This article has been updated with information and comments from Foundation Medicine's earnings call.

NEW YORK (GenomeWeb) – Foundation Medicine reported a 39 percent increase in fourth quarter revenues after the close of market on Tuesday, driven by strong growth from its pharmaceutical business.

The Cambridge, Massachusetts-based firm booked $26.1 million in fourth quarter revenues, up from $18.7 million a year ago, and narrowly beating the consensus Wall Street estimate of $25.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.